Skip to main content
Top
Published in: Urolithiasis 3/2020

Open Access 01-06-2020 | Urolithiasis | Original Paper

The impact of urinary stone disease and their treatment on patients’ quality of life: a qualitative study

Authors: Aditya Raja, Fiona Wood, Hrishi B. Joshi

Published in: Urolithiasis | Issue 3/2020

Login to get access

Abstract

Urinary stone disease is a common, often recurrent disease, that can have a negative impact on patients’ health-related quality of life (HRQoL), often effecting working, productive members of society. The literature lacks data from structured, qualitative research which could give unique insight into patients’ HRQoL. The objective is to understand the impact of urinary stone disease and treatments on patients’ HRQoL, from patients’ and their relatives’ perspective using qualitative and quantitative methodologies. Semi-structured interviews and a focus group were used to understand the HRQoL issues of patients with urinary stones disease, covering the American Urology Association index stone categories. Thematic analysis was performed (using qualitative data analysis software). Familial impact was assessed using the family-related outcome measure (FROM-16©). 62 patients with stone disease and interventions (mean age 51, range 19–92) participated. Data collection stopped when data saturation was achieved. Analysis revealed negative impact of stone disease and interventions on the patients’ HRQoL, affecting domains of pain, physical symptoms, outlook on life, work/career, change in lifestyle/diet, social life, difficulties of daily living, travel/holiday problems, relationships and family member impact (106 themes grouped under ten broad headings). Sub-group analyses revealed similar impact in either sex, ureteric and renal stone groups. Recurrent stones were associated with work/financial concerns and treatment preferences varied accordingly. Our qualitative study presents detailed insights into the multidimensional impact of urinary calculi and their treatments on various domains of the HRQoL, confirming previous findings and adding new observations. The findings are expected to help in the development of patient-centric measures and communication tools.
Literature
3.
go back to reference Wein AJ (2012) Campbell-Walsh urology, 10th edn. WB Saunders, Philedelphia Wein AJ (2012) Campbell-Walsh urology, 10th edn. WB Saunders, Philedelphia
18.
go back to reference Aaronson NK et al (1993) The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85(5):365–376CrossRef Aaronson NK et al (1993) The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85(5):365–376CrossRef
21.
go back to reference Vaughn S, Schumm JS, Sinagub J (1996) Focus group interviews in education and psychology. SAGE Publications, Thousand OaksCrossRef Vaughn S, Schumm JS, Sinagub J (1996) Focus group interviews in education and psychology. SAGE Publications, Thousand OaksCrossRef
24.
go back to reference Seale C (1999) Grounding theory, in quality in qualitative research. SAGE Journals, London, p 214CrossRef Seale C (1999) Grounding theory, in quality in qualitative research. SAGE Journals, London, p 214CrossRef
25.
go back to reference U.S. Department of Health and Human Services FDA Center for Drug Evaluation and Research, U.S. Department of Health and Human Services FDA Center for Biologics Evaluation and Research, U.S. Department of Health and Human Services FDA Center for Devices and Radiological Health (2006) Guidance for industry: patient-reported outcome measures: use in medical product development to support labeling claims: draft guidance. Health Qual Life Outcomes 4(1):79. https://doi.org/10.1186/1477-7525-4-79 CrossRef U.S. Department of Health and Human Services FDA Center for Drug Evaluation and Research, U.S. Department of Health and Human Services FDA Center for Biologics Evaluation and Research, U.S. Department of Health and Human Services FDA Center for Devices and Radiological Health (2006) Guidance for industry: patient-reported outcome measures: use in medical product development to support labeling claims: draft guidance. Health Qual Life Outcomes 4(1):79. https://​doi.​org/​10.​1186/​1477-7525-4-79 CrossRef
Metadata
Title
The impact of urinary stone disease and their treatment on patients’ quality of life: a qualitative study
Authors
Aditya Raja
Fiona Wood
Hrishi B. Joshi
Publication date
01-06-2020
Publisher
Springer Berlin Heidelberg
Keyword
Urolithiasis
Published in
Urolithiasis / Issue 3/2020
Print ISSN: 2194-7228
Electronic ISSN: 2194-7236
DOI
https://doi.org/10.1007/s00240-019-01142-0

Other articles of this Issue 3/2020

Urolithiasis 3/2020 Go to the issue